Date de publication: 5 décembre 2014
Promoteur – Intermédiaire Financier
MERCK KGaALieu
Description
Research and development (R&D) investments in clinical development in the oncology and immunology fields between 2015 and 2018.
Objectifs
The project covers Merck's research activities in oncology and immunology.
Secteur(s)
Montant BEI envisagé (montant approximatif)
EUR 400 million
Coût total (montant approximatif)
EUR 888 million
Aspects environnementaux
The project concerns investments in research and development that will be carried out in existing facilities without changing their already authorised scope. An environmental impact assessment (EIA) is therefore not required by EIA Directive 2011/92/EU. The promoter has an integrated environmental management policy and effective operating procedures in place which are in line with best industry standards.
Passation des marchés
The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU directives on procurement. However, the promoter’s procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank’s services will verify details during the project due diligence.
Statut
Signé - 29/05/2015